Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 4
2021 14
2022 9
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Unknown field was ignored: [Grants and Funding]
Page 1
Editorial: Online Adaptive MR-Guided Radiotherapy.
Kerkmeijer LGW, Valentini V, Fuller CDD, Slotman BJ. Kerkmeijer LGW, et al. Front Oncol. 2021 Aug 30;11:748685. doi: 10.3389/fonc.2021.748685. eCollection 2021. Front Oncol. 2021. PMID: 34527596 Free PMC article. No abstract available.
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling.
Butner JD, Martin GV, Wang Z, Corradetti B, Ferrari M, Esnaola N, Chung C, Hong DS, Welsh JW, Hasegawa N, Mittendorf EA, Curley SA, Chen SH, Pan PY, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W, Koay EJ, Cristini V. Butner JD, et al. Elife. 2021 Nov 9;10:e70130. doi: 10.7554/eLife.70130. Elife. 2021. PMID: 34749885 Free PMC article.
Anderson Cancer Center. We have also received Cancer Center Support Grants from the National Cancer Institute (P30CA016672 to the University of Texas M.D. ...MF was supported through NIH/NCI center grant …
Anderson Cancer Center. We have also received Cancer Center Support Grants from the National Cancer …
Inhibition of the CD47-SIRPalpha axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data.
Son J, Hsieh RC, Lin HY, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS. Son J, et al. Front Immunol. 2022 Nov 11;13:1027235. doi: 10.3389/fimmu.2022.1027235. eCollection 2022. Front Immunol. 2022. PMID: 36439116 Free PMC article.
Of these, 6.4% experienced complete response, 10.4% partial response, and 26.1% stable disease for a 16.7% objective response rate (ORR), 42.8% disease control rate, and 4.8-month median duration of response. ORR was significantly higher for hematologic cancers (25.3%) tha …
Of these, 6.4% experienced complete response, 10.4% partial response, and 26.1% stable disease for a 16.7% objective response rate (ORR), 42 …
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.
Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. Stephen B, et al. J Immunother Cancer. 2023 Aug;11(8):e007236. doi: 10.1136/jitc-2023-007236. J Immunother Cancer. 2023. PMID: 37604642 Free PMC article.
BACKGROUND: Immune checkpoint inhibitors have revolutionized cancer treatment. However, they are associated with a unique spectrum of side effects, called immune-related adverse events (irAEs), which can cause significant morbidity and quickly progress to severe or life-th …
BACKGROUND: Immune checkpoint inhibitors have revolutionized cancer treatment. However, they are associated with a unique spectrum of …
Adhering to Eat and Exercise Status During Radiotherapy for Oropharyngeal Cancer for Prevention and Mitigation of Radiotherapy-Associated Dysphagia.
Barbon CEA, Peterson CB, Moreno AC, Lai SY, Reddy JP, Sahli A, Martino R, Johnson FM, Fuller CD, Hutcheson KA. Barbon CEA, et al. JAMA Otolaryngol Head Neck Surg. 2022 Oct 1;148(10):956-964. doi: 10.1001/jamaoto.2022.2313. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36074459 Free PMC article.
The current study seeks to validate the authors' previously published findings in a large contemporary cohort of patients with oropharynx cancer (OPC) and address limitations of the prior retrospective study using prospective, validated outcome measures. ...MAIN OUTCOMES A …
The current study seeks to validate the authors' previously published findings in a large contemporary cohort of patients with oropharynx …
Impact factor and citation metrics in phase III cancer trials.
Abi Jaoude J, Kouzy R, Rooney M, Thompson P, Patel R, Turner MC, Ghabach M, Fuller CD, Minsky BD, Taniguchi CM, Ludmir EB. Abi Jaoude J, et al. Oncotarget. 2021 Aug 31;12(18):1780-1786. doi: 10.18632/oncotarget.28044. eCollection 2021 Aug 31. Oncotarget. 2021. PMID: 34504650 Free PMC article.
We assessed trial factors associated with the publication of cancer trials in journals with higher IF and publications receiving higher citations. MATERIALS AND METHODS: Cancer-specific phase III RCTs were screened through https://clinicaltrials.gov. ...
We assessed trial factors associated with the publication of cancer trials in journals with higher IF and publications receiving high …
Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization.
Zahid MU, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Zahid MU, et al. J Pers Med. 2021 Nov 1;11(11):1124. doi: 10.3390/jpm11111124. J Pers Med. 2021. PMID: 34834476 Free PMC article.
Although this has led to high control rates for head and neck cancer with 66-70 Gy, this is done without considering patient heterogeneity. ...We also present the results of an in silico trial of this dose personalization using retrospective data from a combined cohort of …
Although this has led to high control rates for head and neck cancer with 66-70 Gy, this is done without considering patient heteroge …
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Vo HH, et al. NPJ Precis Oncol. 2022 Oct 27;6(1):78. doi: 10.1038/s41698-022-00317-0. NPJ Precis Oncol. 2022. PMID: 36302890 Free PMC article.
We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (ClinicalTrials.gov: NCT02152254). Patients with metastatic cancer underwent tumor profiling and were randomized between the two arms whe …
We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (Cli …
Development and Standardization of a Classification System for Osteoradionecrosis: Implementation of a Risk-Based Model.
Watson EE, Hueniken K, Lee J, Huang SH, Maghrabi A AE, Xu W, Moreno AC, Tsai CJ, Hahn E, McPartlin AJ, Yao CM, Goldstein DP, De Almeida JR, Waldon JN, Fuller CD, Hope AJ, Ruggiero SL, Glogauer M, Hosni AA. Watson EE, et al. medRxiv [Preprint]. 2023 Sep 13:2023.09.12.23295454. doi: 10.1101/2023.09.12.23295454. medRxiv. 2023. PMID: 37745576 Free PMC article. Updated. Preprint.
The aim of this study is to identify ORN risk factors and develop a novel classification to depict the severity of ORN. METHODS: Consecutive head-and-neck cancer (HNC) patients treated with curative-intent IMRT ( 45Gy) in 2011-2018 were included. ...
The aim of this study is to identify ORN risk factors and develop a novel classification to depict the severity of ORN. METHODS: Consecutive …
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. Piha-Paul SA, et al. Cancer Chemother Pharmacol. 2023 Aug;92(2):107-118. doi: 10.1007/s00280-023-04545-4. Epub 2023 Jun 14. Cancer Chemother Pharmacol. 2023. PMID: 37314501 Free PMC article. Clinical Trial.
33 results